Progenics Pharmaceuticals (PGNX) Lowered to “Sell” at BidaskClub

BidaskClub lowered shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, BidAskClub reports.

Separately, Zacks Investment Research upgraded Progenics Pharmaceuticals from a hold rating to a buy rating and set a $5.25 target price on the stock in a report on Wednesday, January 16th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. Progenics Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $10.35.

PGNX stock opened at $4.65 on Tuesday. Progenics Pharmaceuticals has a fifty-two week low of $3.62 and a fifty-two week high of $9.42. The company has a current ratio of 4.81, a quick ratio of 4.81 and a debt-to-equity ratio of 0.45. The company has a market cap of $412.57 million, a price-to-earnings ratio of -7.38 and a beta of 2.45.



Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative return on equity of 61.96% and a negative net margin of 436.57%. The firm had revenue of $4.28 million for the quarter, compared to the consensus estimate of $3.71 million. On average, analysts expect that Progenics Pharmaceuticals will post -0.71 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. Quantamental Technologies LLC purchased a new stake in shares of Progenics Pharmaceuticals in the 4th quarter worth approximately $42,000. Amalgamated Bank purchased a new stake in shares of Progenics Pharmaceuticals in the 4th quarter worth approximately $53,000. Advisor Group Inc. grew its stake in shares of Progenics Pharmaceuticals by 2,466.1% in the 4th quarter. Advisor Group Inc. now owns 12,651 shares of the biotechnology company’s stock worth $53,000 after buying an additional 12,158 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Progenics Pharmaceuticals in the 4th quarter worth approximately $55,000. Finally, Boston Advisors LLC purchased a new stake in shares of Progenics Pharmaceuticals in the 4th quarter worth approximately $55,000. Institutional investors own 88.01% of the company’s stock.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Featured Story: What are Bollinger Bands?

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.